Toxicity Risk in DPYD Variant Patients: 5-FU Treatment

This retrospective cohort study delves into the association between DPYD variant alleles and the risk of toxicity from systemic and topical fluoropyrimidine chemotherapy, particularly 5-fluorouracil (5-FU). It emphasizes the importance of understanding the implications of partial and complete DPD deficiency on patient outcomes and the potential clinical benefits of DPYD genetic testing prior to treatment. Through examining the limited existing data, the study highlights the unknown risks and...